Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers

计划入组 80 人 · 首次发布于 2015 年 11 月 4 日

Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A

计划入组 80 人 · 首次发布于 2011 年 7 月 25 日

Clinical Trial Evaluating the Impact of an Intensive Rehabilitation Program Combined With Tendon Vibratory Stimulation on Functional Balance in Individuals With Charcot-Marie-Tooth Disease Type 1A

计划入组 30 人 · 首次发布于 2026 年 7 月 24 日

Charcot-Marie-Tooth Disease Type 1A(Metagenomi)

Beclin activator peripheral (Charcot Marie Tooth disease type 1A)

SARM1 modulator (neurological disorders/Charcot Marie tooth disease type 1A)

CHAS MARIE

France

MARIE CURIE

United Kingdom

FICHOT MARIE

France

Neucore Bio Receives $350K NIH Grant to Develop Exosome-Based Gene Therapy for Charcot-Marie-Tooth Disease

ENCell's Mesenchymal Stem Cell Therapy Shows Promise in First-in-Human Trial for Charcot-Marie-Tooth Disease

Pharnext's CMT1A Drug PXT3003 Fails to Meet Primary Endpoint in Phase 3 PREMIER Trial